Can advanced heart scans predict the biggest killer in Friedreich's ataxia?
NCT ID NCT02316314
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study aims to better understand heart disease in people with Friedreich's ataxia, a genetic disorder that affects coordination and often leads to life-threatening cardiomyopathy. Researchers will use cardiac MRI, echocardiograms, and exercise stress tests to measure heart function and look for early signs of damage. The goal is to identify reliable markers of heart disease that could guide future treatments and monitoring.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to detect and monitor heart disease in people with Friedreich's ataxia, potentially improving care.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve health. The findings may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2015
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will be composed of individuals with FRDA and individuals without FRDA. Individuals without FRDA will be age, gender and ethnicity matched to the individuals with FRDA.
- Ages
-
12 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Friedreich's Ataxia - Inclusion Criteria: * Males and females, age 12 to 50 * Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent) * Definitive diagnosis of FRDA, based on clinical phenotype and genotype * Left ventricle ejection fraction measured by ECHO of \>35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF \<35% will not be required to perform the CPET) Friedreich's Ataxia - Exclusion Criteria: * Signs and symptoms of cardiac failure * Moderate to severe atrial or ventricular arrythmias * History of angina pectoris * Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment * Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR \< 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI) * Females who are pregnant * Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study * Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia * Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus * Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study Normal controls - Inclusion Criteria: * Males and females, age 12 to 30 * Willing and able to provide informed consent (Adolescents will need to provide assent and a parent to provide consent) * Matched age, gender and ethnicity to the FRDA group * Capable of undergoing the various modalities of cardiac assessment * Left ventricle ejection fraction measured by ECHO of \>35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF \<35% will be withdrawn from the study) Normal controls - Exclusion Criteria: * Individuals not deemed in good overall health by the investigator will not be accepted into the study * Signs and symptoms of cardiac failure * Moderate to severe atrial or ventricular arrhythmias * History of angina pectoris * Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment * Any form of dialysis; Severe or end-stage CKD (CKD 4 or 5, eGFR \< 30 ml/min/1.73 m2) without dialysis; eGFR 30 to 40 ml/min/1.73 m2 without dialysis; Acute kidney injury (If a recent assessment is not available, then a blood test to assess kidney function will be performed prior to cardiac MRI) * Females who are pregnant or lactating * Receipt of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to screening, or active enrollment in an investigational medication or device study * Unable to sit with back support * Unable to undergo cardiac MRI with gadolinium contrast or claustrophobia * Unable to undergo exercise tests * Clinical history or evidence of Type 1 or Type 2 Diabetes mellitus * Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his/ her participation in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Friedreich's ataxia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Weill Cornell Medicine
RECRUITINGNew York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a missing protein be replaced to slow Friedreich's ataxia?
- Experimental drug aims to halt rare neurological decline
- New brain scans could reveal hidden clues in rare nerve disease
- Genetic clues may predict when Friedreich's ataxia begins
- Can a supplement and exercise improve stamina in Friedreich's ataxia?
- Exercise and drug combo may fight fatigue in rare disease